SunGen Pharma announced the launch of Busulfan Injection, the second product launch through their joint venture Peterson Athenex with Athenex Pharmaceuticals. The ownership of the approved US ANDA was transferred from Sandoz, a Novartis Division, to SunGen and Athenex. 

The Busulfan Injection is distributed as a prefilled liquid vial with a strength of 6mg/ml in packs of 8. US Market Sales of Busulfan Injection were $33.6M for the year ending December 2018 according to IQVIA data.  Busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.

Dr. Isaac Liu, co-chief executive officer and president of SunGen Pharma, said, “We are proud to add Busulfan Injection to our growing portfolio of specialty injectable products, as well as announce our second product launch through our joint venture. We will continue to look for opportunities to launch products to fill marketplace needs.”

Jeffrey Yordon, Athenex’s chief operating officer and president of Athenex Pharmaceuticals, said, “The launch of Busulfan Injection demonstrates a strong start to our partnership with SunGen Pharma. We look forward to collaborating further to bring specialty pharmaceutical drugs to the market.”